Stratec’s inclusion in the SDAX on June 25, 2025, enhances its visibility ahead of the mwb research Health Care Conference on July 1, where CEO Markus Wolfinger will outline the company’s strategic direction. The event offers timely insight into Stratec’s shift toward high-margin, service-based revenues and platform development. Investors are encouraged to register here: research-hub.de/conference/health-care-conference. As management confirmed its FY25 guidance, with an adjusted EBIT margin of 10–12%, mwb research’s analysts maintain their BUY rating and reaffirm their EUR 32.50 price target, implying an attractive upside. The analysts believe, the SDAX entry could act as a catalyst for increased investor attention and a rerating of the shares. The full update can be downloaded under https://research-hub.de/companies/research/Stratec%20SE

Verbio’s removal from the SDAX on June 23 triggered some short-term technical selling and reduced liquidity from index-tracking funds. However, despite the announcement on June 4, the share price rose by more than 20%, suggesting the market viewed this as a temporary dislocation. Meanwhile, US policy momentum in June 2025, driven by higher Environmental Protection Agency (EPA) biofuel mandates and regulatory clarity, aligns well with Verbio’s strategy. The company’s Nevada-based RNG and bioethanol facility stands to benefit from stronger demand and domestic supply preferences. With deep expertise in biofuels and vertical integration, Verbio is well positioned for growth. While European operations remain stable, the US expansion offers the clearest nearterm upside. US regulatory support and full-scale ramp-up in Nevada could be key catalysts for re-rating. mwb research’s analysts reiterate their BUY rating and maintain their PT of EUR 15.00. The full update can be downloaded under https://www.research-hub.de/companies/Verbio%20SE

Company Name: Desert Gold Ventures Inc. ISIN: CA25039N4084   Reason for the research: Management Interview Recommendation: Buy Target price: 0.311 USD Last rating change: Analyst: Matthias Greiffenberger, Cosmin Filker   GBC AG: The Tiegba project marks Desert Gold’s expansion into the Republic of Côte d’I [ … ]

Company Name: CLINUVEL Pharmaceuticals ISIN: AU000000CUV3   Reason for the research: Research Update Recommendation: Buy from: 23.06.2025 Target price: 22.00 AU$ Target price on sight of: 12 month Last rating change: none Analyst: Thomas Schiessle, Daniel Großjohann CEO Dr. Philippe Wolgen back on board – SCENESSE® [ … ]

Nagarro SE will be included in the TecDAX on 25 June 2025, replacing CompuGroup Medical. The index re-entry enhances visibility and could attract ETF-related inflows. However, Accenture’s recent bookings decline highlights a more cautious enterprise IT spending environment, particularly for discretionary and transformation-led projects. As a result, mwb research’s analysts revise their sales and EBIT estimates downward to reflect softer demand in horizontal tech and early-phase digital engagements. In contrast, verticals like Automotive and Travel remain resilient. Nagarro continues to execute on capital returns and growth, supported by a EUR 400m buyback and its first-ever dividend. At 11.5x P/E and 6.6x EV/EBITDA (2025E), valuation remains attractive. mwb research’s new price target is EUR 92.00 (previously EUR 97.00), reflecting a more balanced near-term view. The full update can be downloaded under https://www.research-hub.de/companies/Nagarro%20SE

Oil prices are climbing amid escalating U.S.–Iran tensions, with Brent nearing USD 80 after Iran’s parliament backed the potential closure of the Strait of Hormuz, a vital shipping corridor responsible for around 20% of global oil flows. A formal shutdown could drive Brent above USD 95, triggering a major shock to global energy markets and disrupting inflation-sensitive supply chains. For BASF, already grappling with margin pressure and softening volumes, a surge in energy costs would further strain its energy intensive operations and heighten the risk of deeper margin compression across key segments, especially in Europe, where energy competitiveness is already under stress. Despite a resilient Q1, mounting Q2 softness and cautious customer sentiment could intensify further if tensions around the Strait of Hormuz escalate. mwb research’s analysts revise their estimates downward and reiterate their BUY rating with a lower price target of EUR 53.00. The full update can be downloaded under https://www.research-hub.de/companies/BASF%20SE

Company Name: Scandinavian Astor Group AB ISIN: SE0019175274   Reason for the research: Update Recommendation: Buy from: 20.06.2025 Target price: 54.00 Target price on sight of: 12 months Last rating change: Analyst: Henry Wendisch Sweden approves SEK 300bn defence booster Yesterday, the Swedish parliament backed the plans to is [ … ]

Company Name: MHP Hotel AG ISIN: DE000A3E5C24   Reason for the research: Update Recommendation: Buy from: 20.06.2025 Target price: 3.00 Target price on sight of: 12 months Last rating change: Analyst: Philipp Sennewald eRS feedback: A lot of opportunities ahead This week, we hit the digital road with MHP CEO Dr Jörg Frehse  [ … ]

tk nucera announced the acquisition of key technology assets from Danish electrolyzer specialist Green Hydrogen Systems (GHS), including intellectual property, a test facility, and an operational prototype in Skive. The transaction, fully funded from existing cash reserves, excludes GHS’s full operations but gives tk nucera access to pressurized alkaline technology designed for dynamic, modular use. GHS’s HyProvide® A- and X Series electrolyzers operate at 30–35 bar and are suited for applications such as hydrogen refueling, power-to-X, and distributed renewables—markets tk nucera had yet to address. This asset deal complements its industrial-scale portfolio and accelerates its R&D capabilities while limiting operational risks. In a still-challenging hydrogen environment, the company is positioning itself strongly for a future rebound. mwb research’s analysts maintain their BUY rating and EUR 12.00 price target, based on their DCF valuation. The full update can be downloaded under https://www.researchhub.de/companies/thyssenkrupp%20nucera%20AG%20&%20Co%20KGaA

Kontron and congatec have signed a term sheet for congatec’s majority acquisition of Kontron’s subsidiary JUMPtec GmbH, including a stake in Kontron America Modules, LLC. This transaction is part of Kontron’s ongoing divestment strategy to streamline operations, unlock capital, and reduce operational complexity. JUMPtec specializes in standardized and customized Computer-on-Modules (COMs) and related design and production services across multiple industries. The deal will generate a high double-digit million euro gain for Kontron through deconsolidation and supports a ‘local-for-local’ production strategy to mitigate geopolitical risks, particularly in the US. mwb research’s analysts reaffirm their BUY rating and price target of EUR 35.00, viewing this deal as value accretive. The full update can be downloaded under: https://www.research-hub.de/companies/research/Kontron%20AG